IRIDEX Cyclo G6™ laser system for glaucoma treatment used in majority of top u.s. ophthalmology hospitals

August 30, 2018
Post Categories: NewsOphthalmic

IRIDEX Corporation, a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophthalmology” as ranked in a recent report by U.S. News and World Report.

The Cyclo G6 system is the first in its class designed specifically to treat patients diagnosed with a range of glaucoma disease states. It features the Company’s proprietary MicroPulse® technology, in which a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period allowing the tissue to cool between laser pulses.

U.S. News and World Report’s “Best Hospitals: Specialty Rankings” is provided annually with a focus on identifying hospitals that excel in treating particularly difficult patients. In the 2017-2018 rankings, over 4,500 U.S. hospitals were evaluated. Specialty hospitals must meet a volume/discharge threshold and be recommended by a minimum number of specialists.

“I have been using the MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) procedure with the Cyclo G6 laser and the MicroPulse P3 probe for more than two years. MicroPulse mode has proven to be an efficacious choice for many of my glaucoma patients, providing significant reduction in pressure and medication use. I have found that after MP-TSCPC procedures, my patients experience less pain and post-procedural inflammation than after traditional Cyclophotocoagulation (CPC),” said Dr. Jonathan S. Myers, Chief Glaucoma Service at Wills Eye Hospital.

Since its launch in 2015, approximately 1,100 G6 systems and approximately 90,000 G6 probes have been shipped to over 50 countries.

“A key component of our strategy in the U.S. is building and expanding relationships with the largest and best ophthalmology hospitals in the country. We are delighted to see most of the facilities named in this report already on the IRIDEX customer list. We believe this both validates our technology and demonstrates the opportunity we have to expand utilization within a wide range of notable institutions,” said William Moore, Chief Executive Officer of IRIDEX.

Source